{"entity":{"id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of EB-DUO-CAR-NK-CEA/GCC (IV) in colorectal cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07462650 by Beijing Biotech, with 48 participants planned, started 2026-02-01 and due to reach its primary completion in 2027-12-21. Interventions recorded: EB-DUO-CAR-NK-CEA/GCC (IV).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07462650","url":"https://clinicaltrials.gov/study/NCT07462650"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","her2-amplified-colorectal"],"sections":[],"technologies":[],"targets":["her2","ceacam5"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07462650","phase":"1/2","setting":"A Phase 1/2, Biomarker-Assigned, Open-Label Dose Escalation and Expansion Study of Allogeneic Dual-Target CAR-NK Cells Targeting CEA (CEACAM5) and/or GUCY2C (GCC) With an Exploratory HER2/ERBB2-Positive Cohort in Subjects With Advanced or Metastatic Colorectal Cancer","sponsor":"Beijing Biotech","started":"2026-02-01","startedType":"actual","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07462650/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"}],"target":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}]}}